CancerSCHSNCT03356340
The Singapore Chinese Health Study
An observational study of Cancer and End Stage Renal Disease, run by Duke-NUS Graduate Medical School.
Trial summary
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United States of America. Read more about this study
- Who is it for?
- Ages 45 to 74 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer, End Stage Renal Disease, Diabetes
- How many people
- 63,257 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 1993to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 74 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study was established between April 1993 and December 1998 through the recruitment of a residential cohort of 63,257 Chinese men (n=27,959) and women (n=35,298), who were aged 45-74 years, and residing in public housing estates.
Who may be able to join
- Housing estate residents, ages 45-74 years, Chinese
Who cannot join
- None
About this study
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United States of America. This is a long-term study to help doctors and scientists understand the influence of diet, lifestyle and environment on the development of common diseases among Singaporean men and women. This includes cancer, heart disease, stroke, dementia, osteoporosis, high cholesterol and diabetes. The aim is to help us understand the causes of these diseases and to discover effective and efficient approaches for prevention and treatment.
Read the detailed description
The cohort consists of more than 60,000 men and women who were enrolled in the Singapore Chinese Health Study during 1993-1998. At the time of enrollment, participants were interviewed in-person regarding their dietary habits and other lifestyle factors. About half of them also donated small amounts of blood and urine for research between 2000 and 2004.
- Conditions
- Cancer, End Stage Renal Disease, Diabetes, Cardiovascular Diseases
- Medical subject headings
- Neoplasms, Kidney Failure, Chronic, Diabetes Mellitus, Cardiovascular Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer incidence
Linkage to national cancer registry
Measured: 1993 to 2025
End-stage Renal Disease
Linkage to national renal registry
Measured: 1993 to 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2017
- Study start1 Apr 1993
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 63,257 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke-NUS Graduate Medical School
- Sponsor type
- University, hospital or other
- Collaborators
- National University of Singapore
- Responsible party
- Principal investigator, Woon-Puay Koh, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03356340
- Sponsor's protocol ID
- SCHS
- Acronym
- SCHS
- Status last verified
- Aug 2021
- First submitted
- 23 Nov 2017
- Last updated
- 20 Aug 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Seah JYH, Ong CN, Koh WP, Yuan JM, van Dam RM. A Dietary Pattern Derived from Reduced Rank Regression and Fatty Acid Biomarkers Is Associated with Lower Risk of Type 2 Diabetes and Coronary Artery Disease in Chinese Adults. J Nutr. 2019 Nov 1;149(11):2001-2010. doi: 10.1093/jn/nxz164.
PubMed 31386157Seah JYH, Koh WP, Yuan JM, van Dam RM. Rice intake and risk of type 2 diabetes: the Singapore Chinese Health Study. Eur J Nutr. 2019 Dec;58(8):3349-3360. doi: 10.1007/s00394-018-1879-7. Epub 2018 Dec 10.
PubMed 30535795Lew QJ, Jafar TH, Jin A, Yuan JM, Koh WP. Consumption of Coffee but Not of Other Caffeine-Containing Beverages Reduces the Risk of End-Stage Renal Disease in the Singapore Chinese Health Study. J Nutr. 2018 Aug 1;148(8):1315-1322. doi: 10.1093/jn/nxy075.
PubMed 29986029Neelakantan N, Koh WP, Yuan JM, van Dam RM. Diet-Quality Indexes Are Associated with a Lower Risk of Cardiovascular, Respiratory, and All-Cause Mortality among Chinese Adults. J Nutr. 2018 Aug 1;148(8):1323-1332. doi: 10.1093/jn/nxy094.
PubMed 29982724
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Singapore Chinese Health Study
- ClinicalTrials.gov ID
- NCT03356340
- Acronym / sponsor ID
- SCHS / SCHS
- Conditions
- Cancer, End Stage Renal Disease, Diabetes, Cardiovascular Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 63,257 participants (actual)
- Lead sponsor
- Duke-NUS Graduate Medical SchoolUniversity, hospital or other
- Collaborators
- National University of Singapore
- Study start
- 1 Apr 1993 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 29 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United States of America. This is a long-term study to help doctors and scientists understand the influence of diet, lifestyle and environment on the development of common diseases among Singaporean men and women. This includes cancer, heart disease, stroke, dementia, osteoporosis, high cholesterol and diabetes. The aim is to help us understand the causes of these diseases and to discover effective and efficient approaches for prevention and treatment.
Detailed description
The cohort consists of more than 60,000 men and women who were enrolled in the Singapore Chinese Health Study during 1993-1998. At the time of enrollment, participants were interviewed in-person regarding their dietary habits and other lifestyle factors. About half of them also donated small amounts of blood and urine for research between 2000 and 2004.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 45 to 74 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study was established between April 1993 and December 1998 through the recruitment of a residential cohort of 63,257 Chinese men (n=27,959) and women (n=35,298), who were aged 45-74 years, and residing in public housing estates.
Key inclusion criteria (1 listed)
- Housing estate residents, ages 45-74 years, Chinese
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cancer incidence
Time frame: 1993 to 2025
Linkage to national cancer registry
End-stage Renal Disease
Time frame: 1993 to 2025
Linkage to national renal registry
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2021.
- Derived from this study: PubMed 31386157Seah JYH, Ong CN, Koh WP, Yuan JM, van Dam RM. A Dietary Pattern Derived from Reduced Rank Regression and Fatty Acid Biomarkers Is Associated with Lower Risk of Type 2 Diabetes and Coronary Artery Disease in Chinese Adults. J Nutr. 2019 Nov 1;149(11):2001-2010. doi: 10.1093/jn/nxz164.
- Derived from this study: PubMed 30535795Seah JYH, Koh WP, Yuan JM, van Dam RM. Rice intake and risk of type 2 diabetes: the Singapore Chinese Health Study. Eur J Nutr. 2019 Dec;58(8):3349-3360. doi: 10.1007/s00394-018-1879-7. Epub 2018 Dec 10.
- Derived from this study: PubMed 29986029Lew QJ, Jafar TH, Jin A, Yuan JM, Koh WP. Consumption of Coffee but Not of Other Caffeine-Containing Beverages Reduces the Risk of End-Stage Renal Disease in the Singapore Chinese Health Study. J Nutr. 2018 Aug 1;148(8):1315-1322. doi: 10.1093/jn/nxy075.
- Derived from this study: PubMed 29982724Neelakantan N, Koh WP, Yuan JM, van Dam RM. Diet-Quality Indexes Are Associated with a Lower Risk of Cardiovascular, Respiratory, and All-Cause Mortality among Chinese Adults. J Nutr. 2018 Aug 1;148(8):1323-1332. doi: 10.1093/jn/nxy094.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and End Stage Renal Disease, run by Duke-NUS Graduate Medical School.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cancer incidence (time frame: 1993 to 2025). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03356340, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2021.